Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Efficacy of piroxicam for postoperative pain after lower third molar surgery associated with CYP2C8{*}3 and CYP2C9

Texto completo
Autor(es):
Calvo, Adriana Maria ; Zupelari-Goncalves, Paulo ; Dionisio, Thiago Jose ; Brozoski, Daniel Thomas ; Faria, Flavio Augusto ; Santos, Carlos Ferreira
Número total de Autores: 6
Tipo de documento: Artigo Científico
Fonte: JOURNAL OF PAIN RESEARCH; v. 10, p. 1581-1589, 2017.
Citações Web of Science: 2
Resumo

Objective: Nonsteroidal anti-inflammatory drugs (NSAIDs) are metabolized by the cytochrome P450 enzymes (CYPs), predominantly CYP2C8 and CYP2C9. The aim of this study was to evaluate the possible association of polymorphisms in the CYP2C8{*}3 and CYP2C9 genes with the clinical efficacy of oral piroxicam (20 mg daily for 4 days) after lower third molar surgeries with regard to postoperative pain, swelling, trismus, adverse reactions, need for rescue medication and the volunteer's overall satisfaction. Materials and methods: For this purpose, 102 volunteers were genotyped for CYP2C8{*}3 and CYP2C9 polymorphisms. Briefly, genomic DNA was isolated from saliva collected from volunteers subjected to invasive lower third molar surgeries, and the preoperative, intraoperative and postoperative parameters were collected and analyzed. Results: An equal amount of piroxicam sufficiently managed postoperative pain and inflammatory symptoms, with visual analog pain scores typically < 40 mm for all genotypes investigated. Furthermore, only two out of 102 volunteers heterozygous for CYP2C8{*}3 and CYP2C9{*}3 reported adverse side effects. Conclusion: In general, slow metabolizers of piroxicam, who were volunteers with mutant alleles, were indifferent from normal metabolizers with the wild-type alleles and therefore did not require specialized piroxicam doses to manage postoperative pain and inflammation. (AU)

Processo FAPESP: 14/17803-1 - Influência do genótipo do Citocromo P450 (CYP2C9) na eficácia clínica e farmacocinética do Piroxicam após cirurgias de terceiros molares inferiores
Beneficiário:Carlos Ferreira dos Santos
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 09/17851-8 - Influência do genótipo do citocromo P450 (CYP2C9) na eficácia clínica e farmacocinética do piroxicam após cirurgias de terceiros molares inferiores
Beneficiário:Adriana Maria Calvo
Linha de fomento: Bolsas no Brasil - Pós-Doutorado